IceCure Medical Ltd
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $8.2M
- Price
- $2.39
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.45%
- Volume
- 107.5K
About
Headquartered in Caesarea, Israel, and founded in 2006, IceCure Medical Ltd is a medical device enterprise dedicated to inventing, refining, and marketing innovative solutions for treating human tumors through cryoablation, a freezing process. Their primary offering, the ProSense system, provides a specialized cryoablation therapy specifically for breast tumors.
Quick stats
Shares outstanding3.4M
Computed float1.4M
Float / shares40.6%
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001584371
AI Summary
AI-generated1/27
minorbullishclinical trial
West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation
West Cancer Center received IRB approval to begin patient enrollment in IceCure's ChoICE post-marketing study for ProSense cryoablation.
The study focuses on low-risk breast cancer patients aged 70 and older, aiming to generate real-world data across 30 participating sites and 400 patients.
ProSense is the first FDA-authorized cryoablation device for this indication, supported by prior clinical data showing a 3.1% local recurrence rate.